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Abstract 
The exposure of GM 1 molecular species present in the native ganglioside, carrying Cl 8: 1 or C20: 1 long-chain bases (LCB), to Dactylium dendroides 
galactose oxidase was studied. When native GM1 (49.3% Cl 8: 1 and 50.7% C2O:l LCB, respectively), was inserted in dipalmitoylphosphatidylcholine 
vesicles and partially oxidized (lo%), the proportion of C18:l and C20: 1 species in the oxidized GM 1 was 59.6% and 40.4%, respectively, suggesting 
a preferential ction of the enzyme on the shorter species. The V,,, of the enzyme was higher on C18:l GM1 than on C2O:l GMl. The molecular 
species were affected without any preference after partial (10%) oxidation of GM1 incorporated in egg phosphatidylcholine vesicles or in micellar 
form. These data indicate that the exposure of the terminal galactose moiety of GM1 ganglioside to galactose oxidase is affected by the ganglioside 
ceramide composition as well as the phospholipid environment, that presumably determine the distribution (molecular dispersion, segregation) of 
the ganglioside within the membrane. 
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1. Introduction 
Glycosphingolipids are inserted with their ceramide 
portion into the outer leaflet of the plasma membrane, 
their oligosaccharide moiety protruding toward the ex- 
ternal environment. The degree of exposure of the oligo- 
saccharide moiety affects its availability to interact with 
external ligands, like enzymes and antibodies, and con- 
tributes to modulate the function of glycosphingolipids 
(crypticity and antigenicity of glycosphingolipids) [3-51. 
Little is known about the role played by the hydrophobic 
moiety of glycosphingolipids on the exposure of the sac- 
charide portion [3,6,7]. However, the changes of the 
physico-chemical and biochemical properties of the 
membrane caused by insertion of glycosphingolipids [8- 
lo] as well as the intrinsic attitude of glycosphingolipids 
to undergo lateral phase separation [l 11, support the 
notion that the ceramide portion of these molecules do 
affect the exposure and the recognition availability of the 
oligosaccharide portions [6,12,13]. Galactose oxidase 
(GAO; EC 1.1.3.9) from Dactylium dendroides, a model 
of soluble protein interacting with the cell surface, has 
been used to examine the exposure of glycosphingolipid 
oligosaccharide portions in both natural [3,14,15] and 
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Abbreviations: GAO, Galactose oxidase (EC 1.1.3.9); DPPC, dipalmi- 
toylphosphatidylcholine; EPC, egg phosphatidylcholine; LUVs, large 
unilamellar vesicles; LCB, long-chain base; HPLC, high performance 
liquid chromatography; HPTLC, high-performance thin-layer chroma- 
tography; GM 1 -ox, oxidized GM 1; NeuAc, N-acetylneuraminic acid. 
Ganglioside nomenclature follows Svennerholm [1] and the IUPAC- 
IUB recommendations [2]. 
artificial membranes [3,16]. In the present study we stud- 
ied the influence of the long chain base (LCB) compo- 
nents of the ceramide portion of ganglioside GM1 on the 
exposure to GAO of the terminal galactose residue of the 
same ganglioside. The study model was constituted by 
‘native’ GM1 ganglioside from bovine brain or GM1 
molecular species containing a single LCB, Cl&l or 
C20:1, inserted into the outer layer of dipalmi- 
toylphosphatidylcholine (DPPC) or egg phosphati- 
dylcholine (EPC) vesicles, an artificial system mimicking 
the ganglioside distribution in the cell membrane [17]. 
2. Materials and methods 
2.1. Materials 
DPPC and EPC were from Fluka AG (Buchs, Switzerland); GAO 
(1 unit/2.3 pg, as protein) and N-acetylneuraminic acid (NeuAc) from 
Sigma Chemical Co. (St. Louis, MO, USA); Sodium boro-[‘HIhydride 
(6.5 Ci/mmol) from Amersham (Little Chalfont, Buchs, UK). 
2.2. Preparation and radiolabeling ofgangliosides 
Native GM1 ganglioside, homogeneous in the saccharide portion but 
not in the lipid moiety, was extracted and purified from beef brain as 
described [18]. Preparation of GMl, tritium labeled at the 3-position 
of the LCB, and fractionation of native (radiolabeled or not) GM1 
ganglioside into molecular species with homogeneous LCB (C18:l and 
C2O:l) in the erythro configuration was performed as described [19,20]. 
Identification, structural analysis, and purity assays of ganglioside were 
performed as described [20]. The final purity of all gangliosides was 
over 99%. The LCB composition of native GM1 was assessed by HPLC 
[21]. Ganglioside-bound sialic acid (NeuAc) was determined as de- 
scribed [22] using NeuAc as standard. 
2.3. Preparation of LUVs containing GM1 
DPPC and EPC, dried and lyophilized from a chloroform/methanol 
(2:1, v/v) solution, were resuspended in 50 mM Tris-HCI, pH 7.0, and 
extruded 10 times through 10 pm pore filters (Nucleopore, Plessanton, 
CA, USA), using a N, pressure-operated xtruder (Lipoprep, Ottawa, 
Canada). The insertion of native GMl, Cl8:l GM1 or C2O:l GM1 
asymmetrically embedded into the outer leaflet of LUVs was done as 
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described [17,23]. Vesicles containing 10% (molar) GM1 were prepared 
and used within 1 day from the preparation. 
2.4. Preparation of micellar ganglioside dispersions 
A known amount of ganglioside, dissolved in chloroform/methanol 
(2:1, v/v) was dried by a gentle flow of N,, resuspended in 50 mM 
Tris-HCI buffer, pH 7.0, and vortexed. The mixture was allowed to 
stand overnight at room temperature. 
2.5. LCB composition after treatment of GM1 with GAO 
The incubation mixtures contained 0.8 mM native GMl, in micellar 
form or inserted into DPPC (or EPC), LUVs, and known amounts of 
GAO, in a final volume of 50 ~1 of 50 mM Tris-HCI, pH 7.0. 1 U, 0.2 
U and 50 U of GAO were added to GMl/DPPC vesicles, GMI/EPC 
vesicles or micellar GMI, respectively. The oxidation, started by the 
addition of the enzyme, was performed under shaking at 37°C for 
different periods of time to obtain a different extent of oxidation (from 
10% to 99%). At the end, samples were submitted to ganglioside extrac- 
tion [18]; ganglioside extracts were evaporated, lyophilized and dis- 
solved in 50 yl of n-propanollwater (8:2, v/v). [jH]NaBH, (400 /,Ki) 
were then added to reduce oxidized GM1 (GMI-ox) to [‘H]GMl 
[24,25]. To ensure complete reduction, one additional ml of Tris-HCI 
buffer and 100 pmol of NaBH, were added and allowed to react for 5 
min. The samples were dialyzed and lyophilized. C18:l and C2O:l 
[‘H]GMl were separated by reverse-phase HPTLC in the solvent sys- 
tem methanol/acetonitrile/water (18:6:1, v/v/v) and quantitated by a 
radiochemical method [26,27]. Three replicate determinations were per- 
formed in 5 independent experiments. 
2.6. Kinetics of GAO activity on LUV dispersion of C18:I and C2O:I 
GM1 
Incubation mixtures containing, in a final volume of 30 fi1 of 50 mM 
Tris-HCI buffer. DH 7.0. 0.0551 mM C18:l GM1 or C2O:l GM1 (car- 
rying 250,000 dpm corresponding to 0.15 nmol of the corresponding 
radiolabeled molecular species) embedded into DPPC or EPC LUVs; 
1 U (GMl/DPPC LUVs) or 0.2 U of GAO (GMI/EPC LUVs), were 
incubated for given periods of time in order to obtain about 10% 
oxidation. In the control incubation mixtures (blanks), the enzyme was 
omitted. At the end of incubation the samples were submitted to lipid 
extraction and GAO activity was measured by radiochemical quantifi- 
cation [27] of formed GMl-ox, separated from residual GM1 by 
HPTLC in the solvent system chloroform/methanol/water (110:40:6, 
v/v/v) followed by chloroform/methanol/CaC1, 0.2% (50:42: 11, v/v/v). 
Five replicates were performed for each experiment. Unless otherwise 
stated, SD. values were < 7% of the mean values. K,,, and V,,,,, values 
were determined from the double-reciprocal plot according to 
Lineweaver-Burk [28], by linear regression. The correlation constants 
(c) were 0.999 > c > 0.994. 
2.7. Statistical analysis 
The differences were evaluated for statistical significance using Stu- 
dent’s t-test. 
3. Results 
3.1. Treatment of native GM1 with GAO 
Galactose oxidase was allowed to act on native GM1 
embedded in LUVs. The results are reported in Fig. 1. 
The proportion of Cl 8: 1 and C20: 1 species present in the 
starting GM1 at 0 time of incubation was 49.3% and 
50.7%, respectively. When the extent of GM1 oxidation 
was about lo%, the proportion of C18:l and C2O:l spe- 
cies present in GMl-ox, detected through its reduction 
to [3H]GM1, was 59.6% and 40.4%, respectively, using 
DPPC LUVs, and 48.3% and 51.7% using EPC LUVs, 
respectively. The compositional difference between 
treated and untreated DPPC LUVs was statistically 
highly significant (P < 0.01). 
- 
Fig. 1. Molecular species composition of oxidized GM1 formed by 
partial (10%) or exhaustive (99%) GAO oxidation of native GM1 em- 
bedded in LUVs. (A) Native GM1 ganglioside (0 time incubation with 
GAO). (B) Native GMI inserted in DPPC LUVs after exhaustive oxi- 
dation. (C) Native GM1 inserted in DPPC LUVs after partial oxida- 
tion. (D) Native GM1 inserted in EPC LUVs after exhaustive oxida- 
tion. (E) Native GM1 inserted in EPC LUVs after partial oxidation. 
Bars indicate the SD. values. Open bars = C18:l GMI; hatched 
bars = C2O:l GMI. Statistical analysis by Student’s t-test: data in panel 
A vs. data in panel C: P < 0.01 (n = 5). 
A partial (10%) oxidation of native GM1 in micellar 
form produced C 18: 1 and C20: 1 GM 1 -ox in the propor- 
tion of about 51% and 49%, matching the composition 
of starting native GM1 [21]. After exhaustive (99%) en- 
zymatic oxidation of native GM1 embedded in both 
DPPC and EPC LUVs no differences in LCB proportion 
were detected between treated and untreated vesicles 
(Fig. 1). 
3.2. Kinetics of GAO upon C18:l GM1 or C2O:l GM1 
embedded into LUVs 
The V/S plots referring to GAO acting on GM 1 molec- 
ular species in DPPC and EPC LUVs are reported in Fig. 
2A and B. The corresponding values of V,,, and K,,, are 
given in Table 1. In the case of GMllDPPC LUVs the 
activity was higher on the Cl 8:l than the C2O:l species 
(69.9 and 52.9 nmol GMlox.min-‘.mg of protein, re- 
spectively). Similar results were obtained using an 
equimolar mixture of Cl 8: 1 GM 1 and C20: 1 GM 1 (total 
GM 1, 10% molar) inserted in DPPC vesicles. In this case 
radiolabeled C18: 1 GM1 was mixed with cold C20: 1 
GM1 or viceversa (Table 1). For GM1 in EPC vesicles 
the kinetic parameters were alike for the two molecular 
species. K, and V,,, values for the GMl/EPC system 
were significantly different from those obtained for 
GM l/DPPC. 
4. Discussion 
The evidence emerging from the present study is the 
ability of GAO to preferentially affect, at the initial 
stages of oxidation, GM 1 ganglioside molecules carrying 
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C18:I rather than C20: 1 LCBs when inserted in DPPC 
vesicles, but not when inserted in EPC or in micellar 
form. These results show that the capability to affect 
GM1 in dependence of its LCB composition is not an 
intrinsic property of the enzyme but depends on the par- 
ticular features of the membrane-mimicking system con- 
taining the gangliosidic substrate. 
The susceptibility of GM1 molecular species to GAO 
action might be related to differences in the orientation 
of the saccharide chains, depending on the ceramide moi- 
ety composition and controlling accessibility to the en- 
zyme. These possibilities seem to be ruled out by previ- 
ous data [29,30] indicating that the lipid chain length 
does not significantly affect the conformation of sac- 
charide moiety. Moreover, it has been reported that in 
the case of galactosylceramide embedded in PC vesicles 
[lo], GAO preferentially affects the molecular species 
carrying longer lipid chains, their saccharide moiety 
being more exposed above the apolar-polar interface of 
the bilayer. This is an entirely different situation than 
ours. Since it has been shown that GAO is very sensitive 
to the degree of segregation of GM 1 [ 161, we believe that 
the preferential action on C 18: 1 GM 1 rather than C20: 1 
GM1 inserted in DPPC vesicles reflects a difference in 
the extent of lateral phase separation of the two gangli- 
oside species. This possibility is suggested by calorimet- 
ric investigations [11,31] that showed a higher tendency 
to undergo lateral phase separation by C20: 1 than Cl 8: 1 
species in DPPC vesicles. Presumably, the triggering fac- 
tor resides in the difference in length and unsaturation 
between the ganglioside and phospholipid moieties. Of 
course, in case of a different extent of segregation GAO 
would preferentially act on the GM1 molecular species 
that is more molecularly dispersed, or less packed in the 
segregated form. 
In conclusion, the ceramide composition of glyco- 
sphingolipids together with the chemical characteristics 
of the surrounding lipid environment appear to control 
the exposure of the sphingolipid saccharide portions to 
Table 1 
Kinetic parameters of GAO upon Cl 8: 1 GM 1 and C20: 1 GM 1 inserted 
in DPPC or EPC LUVs 
V,,X K, 01M) 
(a) DPPC LUVs 
+ C18:l GM1 (10% mol) 69.9 760 
+ C2O:l GM1 (10% mol) 52.9 770 
+ C18:l GM1 (5%) + C2O:l GM1 (5%) 
(C18:l GMl) 70.0 740 
(C2O:l GMl) 53.1 730 
(b) EPC 
+ C18:l GM1 (10% mol) 210 150 
+ C2O:l GMI (10% mol) 201 160 
a V,,,.., expressed as nmoles of oxidated substrate. min-’ ‘mg protein-‘. 
” 
0.5 1.0 
mM GM1 
Fig. 2. Kinetics of GAO action on GM1 molecular species inserted into 
DPPCLUVs(A)orEPCLUVs(B).r=C18:1GMl;o=C20:1GM1. 
external ligands. As a consequence, some biological 
functions taking place at the plasma membrane level, 
may result to be modulated by the surface features of the 
oligosaccharide moieties protruding from the membrane 
surface. 
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